Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $9.3800 (8.06%) ($8.5400 - $9.9400) on Sun. Aug. 30, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 11.36% (three month average) | RSI | 32 | Latest Price | $9.3800(8.06%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.7% a day on average for past five trading days. | Weekly Trend | HTBX declines -15.4% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting HTBX price | HTBX will decline at least -5.68% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | | | | | Relative Volatility | | | | Market Trend Strength | -5.68% (StdDev 11.36%) | Hourly BBV | 0 () | Intraday Trend | 4.7% | | | |
|
1 - 5 Day Possible Target | $-25.26(-369.3%) | Resistance Level | $11.66 | 5 Day Moving Average | $9.03(3.88%) | 10 Day Moving Average | $9.76(-3.89%) | 20 Day Moving Average | $11.66(-19.55%) | To recent high | -63% | To recent low | 81.1% | Market Cap | $N/A | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |